Severe leucopenia associated with Sitagliptin use

Dario Pitocco; Francesco Zaccardi; Francesca Martini; Giuseppe Scavone; Tittania Musella; Salvatore Caputo; Giovanni Ghirlanda

doi:10.1016/j.diabres.2010.10.004

Severe leucopenia associated with Sitagliptin use

Diabetes Res Clin Pract. 2011 Feb;91(2):e30-2. doi: 10.1016/j.diabres.2010.10.004. Epub 2010 Oct 29.

Authors

Dario Pitocco¹, Francesco Zaccardi, Francesca Martini, Giuseppe Scavone, Tittania Musella, Salvatore Caputo, Giovanni Ghirlanda

Affiliation

¹ Department of Internal Medicine, Diabetes Care Unit, Catholic University School of Medicine, Rome, Italy. dario.pitocco@rm.unicatt.it

PMID: 21035885
DOI: 10.1016/j.diabres.2010.10.004

Abstract

We report the case of a type 2 diabetes subject who developed severe leucopenia associated with treatment with the dipeptidil-peptidase 4 enzyme inhibitor Sitagliptin and highlights DPP4 inhibitors as a possible cause of unexplained hematolgical abnormalities in patients receiving DPP4-inhibitor treatment.

Publication types

Case Reports

MeSH terms

Aged
Diabetes Mellitus, Type 2 / drug therapy*
Humans
Hypoglycemic Agents / adverse effects*
Hypoglycemic Agents / therapeutic use*
Leukopenia / chemically induced*
Leukopenia / diagnosis*
Male
Pyrazines / adverse effects*
Pyrazines / therapeutic use*
Sitagliptin Phosphate
Triazoles / adverse effects*
Triazoles / therapeutic use*

Substances

Hypoglycemic Agents
Pyrazines
Triazoles
Sitagliptin Phosphate